TEXT/SOFT Trials: Analysis of Ovarian Suppression in Breast Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.

Dr. Pagani, director of the breast unit at the Oncology Institute of Southern Switzerland, presented data on the joint analysis of the IBCSG TEXT and SOFT trials during the Plenary Session at the 2014 ASCO Annual Meeting.

Here she discusses how breast cancer patients in these trials responded to different methods of ovarian suppression, the pros and cons for each of the methods used in the two trials and the resulting side effects, as well as her thoughts on whether the increase in cancer-free survival seen with aromatase inhibitors plus ovarian suppression will result in payers being willing to reimburse for it.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content
The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.

Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma

Gina Mauro
June 9th 2025
Article

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Ashley Chan
June 5th 2025
Article

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.